标题: [HCSSA] [Event] 中国精准医疗、医 疗大数据的发展现状和趋势

作者: Harvard CSSA

日期: 2016-02-24




中国精准医疗、医疗大数据的发展现状和趋势

National big data system for precision medicine in China: great opportunities and big challenge


Time: 02/26/2016 7:30pm-9pm

Location: Harvard Main Campus, Cambridge, MA 02138

Please register to get a free ticket with detailed room info:

https://goo.gl/FOOHKy

Language: Chinese


Speaker

楼敬伟博士

上海张江国家转化医学中心主任、上海宝藤生物医药科技股份有限公司董事长

Jingwei Lou M.D. & Ph.D

General Manager, Zhangjiang center for translational Medicine


Introduction of Dr. Lou and Shanghai Biotecan


楼敬伟博士现任上海张江转化医学研发中心主任、上海宝藤生物医药科技股份有限公司董事长。 


宝藤公司专业从事医学大数据集成分析引擎与临床应用的开发、个体化医学检测服务和转化医学产业化研究,致力于建设全球领先的“智能医学”大数据系统。目前,公司在全国范围67家大型三甲医院建立了联合实验室;并积累了疾病相关的海量数据,建立了目前全球最大的医学大数据网络和中国人群的“生命数据库”。 


Doctor Lou Jingwei is now Director of Shanghai Zhangjiang Translational Medicine Research & Development Center and Chairman of Board of Shanghai Biotecan Pharmaceuticals Co., Ltd.


Since its foundation in 2008, Biotecan amassed a world-leading elite team, utilized the most cutting-edge technologies in the industry to conduct multidimensional meta-analysis and deep data mining on the medical big data of genomics and disease clinical information, and established a series of standards for personalized medicine in China. Biotecan has developed a spectrum of clinical diagnostic products for various types of diseases, including screening, early detection, monitoring of disease progression and prognosis. Biotecan is now offering multiple solutions for personalized medicine to patients, doctors and pharmaceutical /biotech companies across China. Currently, Biotecan has launched a catalog of more than 500 clinical molecular diagnosis products, cooperated with more than 400 large “top tier” research hospitals and medical schools nationwide, organized more than 500 sessions of academic lectures per year and provided services to more than 100,000 patients in 2015. Biotecan has been recognized by the State and National government as “an industry leader in tumor molecular diagnosis in China”, “an energetic and innovative high-tech enterprise in Shanghai”, “a key enterprise of biomedicine and bioinformatics at Zhangjiang Hi-Tech Park”, “a constitutive public service platform for personalized medicine in Shanghai”, and is a major facility of “National Center for Translational Science in Molecular Medicine” approved by the State Development and Reform Commission of China.


In the meantime, Biotecan and Zhangjiang CTM have collaborated with many large Grade 3A class hospitals to participate in the construction of national-level research platforms and establish innovative network-style research systems, in order to collect massive data from various types of diseases. Based on the multidimensional meta-analysis and deep data mining on the clinical cases, sample information and omics information, a “big medical database” on the Chinese population has been set up to serve as the foundation for an innovative research system for translational medicine. In the end of 2015, Biotecan has signed or completed the construction of more than 60 joint molecular diagnosis center with many benchmarking Grade 3A class hospitals and large scientific institutions, including Fudan University and The Second Military Medical University, as well as many biomedical industry leaders. Biotecan is striving to synchronize with the world from both academic and industrial aspect to become the leader in precision medicine and practitioner in translational medicine, and aims to provide the best medical service to patients in China with the most advanced technology.


This event is organized by the Harvard Chinese Students and Scholars Association and supported by the Harvard Graduate Student Council.


--
哈佛大学中国学生学者联合会
Harvard Chinese Students and Scholars Association (HCSSA)
Lehman Hall ∙ Harvard University ∙ Cambridge 
Website: www.hcssa.org
Facebook: Harvard CSSA
Twitter: Harvard CSSA
OrgSquare: Harvard CSSA
微博: 哈佛大学中国学联
微信公众号:HarvardCSSA


© 2008 laozhong.net - Jax Systems, LLC, U.S.A